Biomarkers and mechanisms associated with recurrent prostate cancer

Frontiers in Bioscience - Landmark

Volumn 19, Issue 2, 2014, Pages 339-351

  Sharma, Sambad ^a   Watabe, Kounosuke ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Mechanisms; Prostate cancer; Recurrence; Review

Indexed keywords

TUMOR MARKER;

HUMAN; MALE; METABOLISM; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PROSTATE TUMOR; REVIEW; TUMOR RECURRENCE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904368551     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4211     Document Type: Review

References (113)

1. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers and D. M. Parkin: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127(12), 2893-917 (2010)
2. E. Giovannucci, Y. Liu, E. A. Platz, M. J. Stampfer and W. C. Willett: Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer, 121(7), 1571-8 (2007)
3. H. Peinado, S. Rafii and D. Lyden: Inflammation joins the "niche". Cancer Cell, 14(5), 347-9 (2008)
4. M. Marberger, J. Barentsz, M. Emberton, J. Hugosson, S. Loeb, L. Klotz, M. Koch, S. F. Shariat and A. Vickers: Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU Int, 109 Suppl 2, 1-7 (2012)
5. K. A. Roehl, M. Han, C. G. Ramos, J. A. Antenor and W. J. Catalona: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol, 172(3), 910-4 (2004)
6. D. Weckermann, P. Muller, F. Wawroschek, R. Harzmann, G. Riethmuller and G. Schlimok: Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol, 166(2), 699-703 (2001)
7. C. R. Pound, A. W. Partin, M. A. Eisenberger, D. W. Chan, J. D. Pearson and P. C. Walsh: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281(17), 1591-7 (1999)
8. J. Pfitzenmaier, W. J. Ellis, E. W. Arfman, S. Hawley, P. O. McLaughlin, P. H. Lange and R. L. Vessella: Telomerase activity in disseminated prostate cancer cells. BJU Int, 97(6), 1309-13 (2006)
9. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun: Cancer statistics, 2009. CA Cancer J Clin, 59(4), 225-49 (2009)
10. J. P. Thiery: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2(6), 442-54 (2002)
11. H. M. Behnsawy, H. Miyake, K. Harada and M. Fujisawa: Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int, 111(1), 30-7 (2013)
12. K. Pantel and C. Alix-Panabieres: The clinical significance of circulating tumor cells. Nat Clin Pract Oncol, 4(2), 62-3 (2007)
13. K. Polyak and R. A. Weinberg: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer, 9(4), 265-73 (2009)
14. D. X. Nguyen and J. Massague: Genetic determinants of cancer metastasis. Nat Rev Genet, 8(5), 341-52 (2007)
15. S. L. Stott, R. J. Lee, S. Nagrath, M. Yu, D. T. Miyamoto, L. Ulkus, E. J. Inserra, M. Ulman, S. Springer, Z. Nakamura, A. L. Moore, D. I. Tsukrov, M. E. Kempner, D. M. Dahl, C. L. Wu, A. J. Iafrate, M. R. Smith, R. G. Tompkins, L. V. Sequist, M. Toner, D. A. Haber and S. Maheswaran: Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med, 2(25), 25ra23 (2010)
16. J. G. Moreno, M. C. Miller, S. Gross, W. J. Allard, L. G. Gomella and L. W. Terstappen: Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology, 65(4), 713-8 (2005)
17. T. M. Morgan, P. H. Lange, M. P. Porter, D. W. Lin, W. J. Ellis, I. S. Gallaher and R. L. Vessella: Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res, 15(2), 677-83 (2009)
18. R. B. Verkooijen, J. W. Smit, J. A. Romijn and M. P. Stokkel: The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol, 155(6), 801-6 (2006)
19. R. Toivanen, M. Frydenberg, D. Murphy, J. Pedersen, A. Ryan, D. Pook, D. M. Berman, B. Australian Prostate Cancer, R. A. Taylor and G. P. Risbridger: A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors. Sci Transl Med, 5(187), 187ra71 (2013)
20. K. Pantel and R. H. Brakenhoff: Dissecting the metastatic cascade. Nat Rev Cancer, 4(6), 448-56 (2004)
21. J. S. de Bono, H. I. Scher, R. B. Montgomery, C. Parker, M. C. Miller, H. Tissing, G. V. Doyle, L. W. Terstappen, K. J. Pienta and D. Raghavan: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res, 14(19), 6302-9 (2008)
22. G. N. Naumov, I. C. MacDonald, A. F. Chambers and A. C. Groom: Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol, 11(4), 271-6 (2001)
23. G. N. Naumov, I. C. MacDonald, P. M. Weinmeister, N. Kerkvliet, K. V. Nadkarni, S. M. Wilson, V. L. Morris, A. C. Groom and A. F. Chambers: Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res, 62(7), 2162-8 (2002)
24. P. Gassmann and J. Haier: The tumor cell-host organ interface in the early onset of metastatic organ colonisation. Clin Exp Metastasis, 25(2), 171-81 (2008)
25. N. Hanna and R. C. Burton: Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J Immunol, 127(5), 1754-8 (1981)
26. B. Nieswandt, M. Hafner, B. Echtenacher and D. N. Mannel: Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res, 59(6), 1295-300 (1999)
27. J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La Jeunesse, M. J. Flick, K. W. Kombrinck, M. Jirouskova and J. L. Degen: Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood, 105(1), 178-85 (2005)
28. A. Kobayashi, H. Okuda, F. Xing, P. R. Pandey, M. Watabe, S. Hirota, S. K. Pai, W. Liu, K. Fukuda, C. Chambers, A. Wilber and K. Watabe: Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med, 208(13), 2641-55 (2011)
29. J. H. Tsai, J. L. Donaher, D. A. Murphy, S. Chau and J. Yang: Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell, 22(6), 725-36 (2012)
30. M. Yu, A. Bardia, B. S. Wittner, S. L. Stott, M. E. Smas, D. T. Ting, S. J. Isakoff, J. C. Ciciliano, M. N. Wells, A. M. Shah, K. F. Concannon, M. C. Donaldson, L. V. Sequist, E. Brachtel, D. Sgroi, J. Baselga, S. Ramaswamy, M. Toner, D. A. Haber and S. Maheswaran: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science, 339(6119), 580-4 (2013)
31. D. Kong, S. Banerjee, A. Ahmad, Y. Li, Z. Wang, S. Sethi and F. H. Sarkar: Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One, 5(8), e12445 (2010)
32. Y. Shi and J. Massague: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 113(6), 685-700 (2003)
33. J. Zavadil and E. P. Bottinger: TGF-beta and epithelial-to-mesenchymal transitions. Oncogene, 24(37), 5764-74 (2005)
34. J. Zavadil, L. Cermak, N. Soto-Nieves and E. P. Bottinger: Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J, 23(5), 1155-65 (2004)
35. H. E. Zhau, V. Odero-Marah, H. W. Lue, T. Nomura, R. Wang, G. Chu, Z. R. Liu, B. P. Zhou, W. C. Huang and L. W. Chung: Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis, 25(6), 601-10 (2008)
36. S. Santagata, F. Demichelis, A. Riva, S. Varambally, M. D. Hofer, J. L. Kutok, R. Kim, J. Tang, J. E. Montie, A. M. Chinnaiyan, M. A. Rubin and J. C. Aster: JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res, 64(19), 6854-7 (2004)
37. S. J. Mancini, N. Mantei, A. Dumortier, U. Suter, H. R. MacDonald and F. Radtke: Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. Blood, 105(6), 2340-2 (2005)
38. F. Xing, A. Kobayashi, H. Okuda, M. Watabe, S. K. Pai, P. R. Pandey, S. Hirota, A. Wilber, Y. Y. Mo, B. E. Moore, W. Liu, K. Fukuda, M. Iiizumi, S. Sharma, Y. Liu, K. Wu, E. Peralta and K. Watabe: Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain. EMBO Mol Med, 5(3), 384-96 (2013)
39. L. A. Timmerman, J. Grego-Bessa, A. Raya, E. Bertran, J. M. Perez-Pomares, J. Diez, S. Aranda, S. Palomo, F. McCormick, J. C. Izpisua-Belmonte and J. L. de la Pompa: Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev, 18(1), 99-115 (2004)
40. Z. Wang, Y. Li, S. Banerjee, D. Kong, A. Ahmad, V. Nogueira, N. Hay and F. H. Sarkar: Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem, 109(4), 726-36 (2010)
41. P. Wikstrom, P. Stattin, I. Franck-Lissbrant, J. E. Damber and A. Bergh: Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate, 37(1), 19-29 (1998)
42. R. J. Akhurst and R. Derynck: TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol, 11(11), S44-51 (2001)
43. J. Han and P. Sun: The pathways to tumor suppression via route p38. Trends Biochem Sci, 32(8), 364-71 (2007)
44. H. Hanafusa, J. Ninomiya-Tsuji, N. Masuyama, M. Nishita, J. Fujisawa, H. Shibuya, K. Matsumoto and E. Nishida: Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem, 274(38), 27161-7 (1999)
45. J. A. Hickson, D. Huo, D. J. Vander Griend, A. Lin, C. W. Rinker-Schaeffer and S. D. Yamada: The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res, 66(4), 2264-70 (2006)
46. Y. Shiozawa, E. A. Pedersen, A. M. Havens, Y. Jung, A. Mishra, J. Joseph, J. K. Kim, L. R. Patel, C. Ying, A. M. Ziegler, M. J. Pienta, J. Song, J. Wang, R. D. Loberg, P. H. Krebsbach, K. J. Pienta and R. S. Taichman: Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest, 121(4), 1298-312 (2011)
47. Y. Jung, J. Wang, J. Song, Y. Shiozawa, J. Wang, A. Havens, Z. Wang, Y. X. Sun, S. G. Emerson, P. H. Krebsbach and R. S. Taichman: Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood, 110(1), 82-90 (2007)
48. M. F. Pittenger, A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca, M. A. Moorman, D. W. Simonetti, S. Craig and D. R. Marshak: Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411), 143-7 (1999)
49. A. Sugihara, O. Maeda, M. Tsuji, T. Tsujimura, Y. Nakata, H. Akedo, T. Kotake and N. Terada: Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: an immunohistochemical study. Oncol Rep, 5(6), 1389-94 (1998)
50. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison and M. F. Clarke: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A, 100(7), 3983-8 (2003)
51. R. S. Taichman, C. Cooper, E. T. Keller, K. J. Pienta, N. S. Taichman and L. K. McCauley: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res, 62(6), 1832-7 (2002)
52. Y. X. Sun, J. Wang, C. E. Shelburne, D. E. Lopatin, A. M. Chinnaiyan, M. A. Rubin, K. J. Pienta and R. S. Taichman: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem, 89(3), 462-73 (2003)
53. Y. X. Sun, A. Schneider, Y. Jung, J. Wang, J. Dai, J. Wang, K. Cook, N. I. Osman, A. J. Koh-Paige, H. Shim, K. J. Pienta, E. T. Keller, L. K. McCauley and R. S. Taichman: Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res, 20(2), 318-29 (2005)
54. Y. Shiozawa, E. A. Pedersen, L. R. Patel, A. M. Ziegler, A. M. Havens, Y. Jung, J. Wang, S. Zalucha, R. D. Loberg, K. J. Pienta and R. S. Taichman: GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia, 12(2), 116-27 (2010)
55. C. Gjerdrum, C. Tiron, T. Hoiby, I. Stefansson, H. Haugen, T. Sandal, K. Collett, S. Li, E. McCormack, B. T. Gjertsen, D. R. Micklem, L. A. Akslen, C. Glackin and J. B. Lorens: Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A, 107(3), 1124-9 (2010)
56. T. H. van der Kwast, J. Schalken, J. A. Ruizeveld de Winter, C. C. van Vroonhoven, E. Mulder, W. Boersma and J. Trapman: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer, 48(2), 189-93 (1991)
57. T. Visakorpi, E. Hyytinen, P. Koivisto, M. Tanner, R. Keinanen, C. Palmberg, A. Palotie, T. Tammela, J. Isola and O. P. Kallioniemi: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet, 9(4), 401-6 (1995)
58. R. de Vere White, F. Meyers, S. G. Chi, S. Chamberlain, D. Siders, F. Lee, S. Stewart and P. H. Gumerlock: Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol, 31(1), 1-6 (1997)
59. C. W. Gregory, B. He, R. T. Johnson, O. H. Ford, J. L. Mohler, F. S. French and E. M. Wilson: A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res, 61(11), 4315-9 (2001)
60. G. Buchanan, M. Yang, J. M. Harris, H. S. Nahm, G. Han, N. Moore, J. M. Bentel, R. J. Matusik, D. J. Horsfall, V. R. Marshall, N. M. Greenberg and W. D. Tilley: Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol, 15(1), 46-56 (2001)
61. B. Gottlieb, L. K. Beitel, J. H. Wu and M. Trifiro: The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat, 23(6), 527-33 (2004)
62. B. J. Feldman and D. Feldman: The development of androgen-independent prostate cancer. Nat Rev Cancer, 1(1), 34-45 (2001)
63. E. P. Gelmann: Molecular biology of the androgen receptor. J Clin Oncol, 20(13), 3001-15 (2002)
64. M. E. Grossmann, H. Huang and D. J. Tindall: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst, 93(22), 1687-97 (2001)
65. R. Stege, B. Tribukait, B. Lundh, K. Carlstrom, A. Pousette and M. Hasenson: Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J Urol, 148(3), 833-7 (1992)
66. J. L. Mohler, C. W. Gregory, O. H. Ford, 3rd, D. Kim, C. M. Weaver, P. Petrusz, E. M. Wilson and F. S. French: The androgen axis in recurrent prostate cancer. Clin Cancer Res, 10(2), 440-8 (2004)
67. Z. Guo, X. Yang, F. Sun, R. Jiang, D. E. Linn, H. Chen, H. Chen, X. Kong, J. Melamed, C. G. Tepper, H. J. Kung, A. M. Brodie, J. Edwards and Y. Qiu: A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res, 69(6), 2305-13 (2009)
68. S. Sun, C. C. Sprenger, R. L. Vessella, K. Haugk, K. Soriano, E. A. Mostaghel, S. T. Page, I. M. Coleman, H. M. Nguyen, H. Sun, P. S. Nelson and S. R. Plymate: Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest, 120(8), 2715-30 (2010)
69. R. Hu, T. A. Dunn, S. Wei, S. Isharwal, R. W. Veltri, E. Humphreys, M. Han, A. W. Partin, R. L. Vessella, W. B. Isaacs, G. S. Bova and J. Luo: Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res, 69(1), 16-22 (2009)
70. R. A. Ghossein, H. I. Scher, W. L. Gerald, W. K. Kelly, T. Curley, A. Amsterdam, Z. F. Zhang and J. Rosai: Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol, 13(5), 1195-200 (1995)
71. G. Attard, J. F. Swennenhuis, D. Olmos, A. H. Reid, E. Vickers, R. A'Hern, R. Levink, F. Coumans, J. Moreira, R. Riisnaes, N. B. Oommen, G. Hawche, C. Jameson, E. Thompson, R. Sipkema, C. P. Carden, C. Parker, D. Dearnaley, S. B. Kaye, C. S. Cooper, A. Molina, M. E. Cox, L. W. Terstappen and J. S. de Bono: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res, 69(7), 2912-8 (2009)
72. A. Hobisch, Z. Culig, C. Radmayr, G. Bartsch, H. Klocker and A. Hittmair: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res, 55(14), 3068-72 (1995)
73. X. Y. Zhao, P. J. Malloy, A. V. Krishnan, S. Swami, N. M. Navone, D. M. Peehl and D. Feldman: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med, 6(6), 703-6 (2000)
74. A. Y. Liu, E. Corey, F. Bladou, P. H. Lange and R. L. Vessella: Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer, 65(1), 85-9 (1996)
75. P. S. Steeg: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer, 3(1), 55-63 (2003)
76. Z. Fu, Y. Kitagawa, R. Shen, R. Shah, R. Mehra, D. Rhodes, P. J. Keller, A. Mizokami, R. Dunn, A. M. Chinnaiyan, Z. Yao and E. T. Keller: Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate, 66(3), 248-56 (2006)
77. S. Bandyopadhyay, S. K. Pai, S. C. Gross, S. Hirota, S. Hosobe, K. Miura, K. Saito, T. Commes, S. Hayashi, M. Watabe and K. Watabe: The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res, 63(8), 1731-6 (2003)
78. S. Bandyopadhyay, R. Zhan, A. Chaudhuri, M. Watabe, S. K. Pai, S. Hirota, S. Hosobe, T. Tsukada, K. Miura, Y. Takano, K. Saito, M. E. Pauza, S. Hayashi, Y. Wang, S. Mohinta, T. Mashimo, M. Iiizumi, E. Furuta and K. Watabe: Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med, 12(8), 933-8 (2006)
79. E. M. Eves, P. Shapiro, K. Naik, U. R. Klein, N. Trakul and M. R. Rosner: Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell, 23(4), 561-74 (2006)
80. K. Yeung, T. Seitz, S. Li, P. Janosch, B. McFerran, C. Kaiser, F. Fee, K. D. Katsanakis, D. W. Rose, H. Mischak, J. M. Sedivy and W. Kolch: Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature, 401(6749), 173-7 (1999)
81. K. Yeung, P. Janosch, B. McFerran, D. W. Rose, H. Mischak, J. M. Sedivy and W. Kolch: Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol, 20(9), 3079-85 (2000)
82. J. A. Aguirre-Ghiso, Y. Estrada, D. Liu and L. Ossowski: ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res, 63(7), 1684-95 (2003)
83. J. A. Aguirre-Ghiso, D. Liu, A. Mignatti, K. Kovalski and L. Ossowski: Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell, 12(4), 863-79 (2001)
84. G. Chen, M. Hitomi, J. Han and D. W. Stacey: The p38 pathway provides negative feedback for Ras proliferative signaling. J Biol Chem, 275(50), 38973-80 (2000)
85. R. Haq, J. D. Brenton, M. Takahashi, D. Finan, A. Finkielsztein, S. Damaraju, R. Rottapel and B. Zanke: Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res, 62(17), 5076-82 (2002)
86. D. F. Gleason: Classification of prostatic carcinomas. Cancer Chemother Rep, 50(3), 125-8 (1966)
87. P. S. Bunting: Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta, 315(1-2), 71-97 (2002)
88. S. J. Freedland, E. B. Humphreys, L. A. Mangold, M. Eisenberger, F. J. Dorey, P. C. Walsh and A. W. Partin: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA, 294(4), 433-9 (2005)
89. C. Cordon-Cardo, A. Kotsianti, D. A. Verbel, M. Teverovskiy, P. Capodieci, S. Hamann, Y. Jeffers, M. Clayton, F. Elkhettabi, F. M. Khan, M. Sapir, V. Bayer-Zubek, Y. Vengrenyuk, S. Fogarsi, O. Saidi, V. E. Reuter, H. I. Scher, M. W. Kattan, F. J. Bianco, T. M. Wheeler, G. E. Ayala, P. T. Scardino and M. J. Donovan: Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest, 117(7), 1876-83 (2007)
90. I. U. Agoulnik, A. Vaid, M. Nakka, M. Alvarado, W. E. Bingman, 3rd, H. Erdem, A. Frolov, C. L. Smith, G. E. Ayala, M. M. Ittmann and N. L. Weigel: Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res, 66(21), 10594-602 (2006)
91. P. Kahl, L. Gullotti, L. C. Heukamp, S. Wolf, N. Friedrichs, R. Vorreuther, G. Solleder, P. J. Bastian, J. Ellinger, E. Metzger, R. Schule and R. Buettner: Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res, 66(23), 11341-7 (2006)
92. B. S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B. S. Carver, V. K. Arora, P. Kaushik, E. Cerami, B. Reva, Y. Antipin, N. Mitsiades, T. Landers, I. Dolgalev, J. E. Major, M. Wilson, N. D. Socci, A. E. Lash, A. Heguy, J. A. Eastham, H. I. Scher, V. E. Reuter, P. T. Scardino, C. Sander, C. L. Sawyers and W. L. Gerald: Integrative genomic profiling of human prostate cancer. Cancer Cell, 18(1), 11-22 (2010)
93. J. J. Bauer, I. A. Sesterhenn, F. K. Mostofi, D. G. McLeod, S. Srivastava and J. W. Moul: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol, 156(4), 1511-6 (1996)
94. S. Loric, V. Paradis, J. L. Gala, P. Berteau, P. Bedossa, G. Benoit and P. Eschwege: Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. Eur J Cancer, 37(12), 1475-81 (2001)
95. S. Aaltomaa, P. Lipponen, R. Tammi, M. Tammi, J. Viitanen, J. P. Kankkunen and V. M. Kosma: Strong Stromal Hyaluronan Expression Is Associated with PSA Recurrence in Local Prostate Cancer. Urol Int, 69(4), 266-72 (2002)
96. S. J. McAlhany, G. E. Ayala, A. Frolov, S. J. Ressler, T. M. Wheeler, J. E. Watson, C. Collins and D. R. Rowley: Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival. Prostate, 61(2), 182-91 (2004)
97. G. Ayala, J. A. Tuxhorn, T. M. Wheeler, A. Frolov, P. T. Scardino, M. Ohori, M. Wheeler, J. Spitler and D. R. Rowley: Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res, 9(13), 4792-801 (2003)
98. M. R. Pins, J. E. Fiadjoe, F. Korley, M. Wong, A. W. Rademaker, B. Jovanovic, T. K. Yoo, J. M. Kozlowski, A. Raji, X. J. Yang and C. Lee: Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis, 7(3), 243-8 (2004)
99. G. L. Andriole, E. D. Crawford, R. L. Grubb, 3rd, S. S. Buys, D. Chia, T. R. Church, M. N. Fouad, E. P. Gelmann, P. A. Kvale, D. J. Reding, J. L. Weissfeld, L. A. Yokochi, B. O'Brien, J. D. Clapp, J. M. Rathmell, T. L. Riley, R. B. Hayes, B. S. Kramer, G. Izmirlian, A. B. Miller, P. F. Pinsky, P. C. Prorok, J. K. Gohagan, C. D. Berg and P. P. Team: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med, 360(13), 1310-9 (2009)
100. F. H. Schroder, J. Hugosson, M. J. Roobol, T. L. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L. J. Denis, F. Recker, A. Berenguer, L. Maattanen, C. H. Bangma, G. Aus, A. Villers, X. Rebillard, T. van der Kwast, B. G. Blijenberg, S. M. Moss, H. J. de Koning, A. Auvinen and E. Investigators: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med, 360(13), 1320-8 (2009)
101. M. K. Brawer: Prostate-specific antigen: current status. CA Cancer J Clin, 49(5), 264-81 (1999)
102. D. C. Danila, M. Fleisher and H. I. Scher: Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res, 17(12), 3903-12 (2011)
103. E. A. Punnoose, S. K. Atwal, J. M. Spoerke, H. Savage, A. Pandita, R. F. Yeh, A. Pirzkall, B. M. Fine, L. C. Amler, D. S. Chen and M. R. Lackner: Molecular biomarker analyses using circulating tumor cells. PLoS One, 5(9), e12517 (2010)
104. D. C. Danila, G. Heller, G. A. Gignac, R. Gonzalez-Espinoza, A. Anand, E. Tanaka, H. Lilja, L. Schwartz, S. Larson, M. Fleisher and H. I. Scher: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res, 13(23), 7053-8 (2007)
105. D. R. Shaffer, M. A. Leversha, D. C. Danila, O. Lin, R. Gonzalez-Espinoza, B. Gu, A. Anand, K. Smith, P. Maslak, G. V. Doyle, L. W. Terstappen, H. Lilja, G. Heller, M. Fleisher and H. I. Scher: Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res, 13(7), 2023-9 (2007)
106. M. C. Bettencourt, J. J. Bauer, I. A. Sesterhenn, R. R. Connelly and J. W. Moul: CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol, 160(2), 459-65 (1998)
107. S. Bettuzzi, M. Scaltriti, A. Caporali, M. Brausi, D. D'Arca, S. Astancolle, P. Davalli and A. Corti: Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study. Cancer Res, 63(13), 3469-72 (2003)
108. P. G. Febbo and W. R. Sellers: Use of expression analysis to predict outcome after radical prostatectomy. J Urol, 170(6 Pt 2), S11-9; discussion S19-20 (2003)
109. D. Singh, P. G. Febbo, K. Ross, D. G. Jackson, J. Manola, C. Ladd, P. Tamayo, A. A. Renshaw, A. V. D'Amico, J. P. Richie, E. S. Lander, M. Loda, P. W. Kantoff, T. R. Golub and W. R. Sellers: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell, 1(2), 203-9 (2002)
110. D. B. Seligson, S. Horvath, T. Shi, H. Yu, S. Tze, M. Grunstein and S. K. Kurdistani: Global histone modification patterns predict risk of prostate cancer recurrence. Nature, 435(7046), 1262-6 (2005)
111. A. Kirmizis, S. M. Bartley, A. Kuzmichev, R. Margueron, D. Reinberg, R. Green and P. J. Farnham: Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev, 18(13), 1592-605 (2004)
112. J. Yu, J. Yu, D. R. Rhodes, S. A. Tomlins, X. Cao, G. Chen, R. Mehra, X. Wang, D. Ghosh, R. B. Shah, S. Varambally, K. J. Pienta and A. M. Chinnaiyan: A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res, 67(22), 10657-63 (2007)
113. A. van de Stolpe, K. Pantel, S. Sleijfer, L. W. Terstappen and J. M. den Toonder: Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res, 71(18), 5955-60 (2011)